America's Poison Centers
US$ 23.16
asa statement on glp 1 Perioperative management of patients taking glucagon-like peptide-1 receptor agonists: a restrictive fasting regimen is not necessary. Comment Br J Anaesth 2025; 135: 48–78 Are Serious Anesthesia Risks of
Description
Bariatric Surgery versus Intensive Medical Therapy for Diabetes 5-Year Outcomes
Changes in body weight and self-reported depressive symptoms from baseline to 56 weeks were assessed as coprimary endpoints
A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD
Combining insights from the ESG Risk Rating and Morningstar Equity Research, we find that Roche and Pfizer stand out as potential top choices among the companies poised to enter the GLP-1 space
The inhibition of the onset and progression of DKD is an urgent issue, and the development of therapeutic approaches against DKD is required
